基于更新版放射治疗肿瘤学组/国家研究组与欧洲癌症研究与治疗组织指南的不同靶区勾画在3-4级胶质瘤患者放疗中的毒性与疗效:一项随机对照临床试验
该随机对照试验纳入245例新诊断WHO 3-4级胶质瘤患者,按1:1随机接受术后放疗联合同期及维持替莫唑胺化疗,分别采用更新版RTOG/NRG指南(n=122)或EORTC指南(n=123)勾画靶区。两组低级别或高级别毒性均无差异,均无5级毒性,神经毒性无显著差异;中位PFS分别为11.0个月与10.0个月(P=.73),中位OS分别为19.5个月与18.5个月(P=.80)。在IDH野生型胶质母细胞瘤亚组中,两组中位PFS和OS亦无显著差异。
要点
- 两组低级别或高级别毒性均无差异,均未出现5级毒性
- RTOG/NRG组与EORTC组中位PFS分别为11.0个月与10.0个月,差异无统计学意义(P=.73)
- RTOG/NRG组与EORTC组中位OS分别为19.5个月与18.5个月,差异无统计学意义(P=.80)
核心结论
- 与EORTC原则相比,按照RTOG/NRG原则进行术后放疗未增加治疗相关毒性,且对3-4级胶质瘤患者疗效相当,包括IDH野生型胶质母细胞瘤亚组。
研究设计与样本
- 随机对照临床试验,纳入245例新诊断WHO 3-4级胶质瘤患者,按1:1随机分配接受术后放疗联合同期及维持替莫唑胺化疗。
- 放疗靶区勾画分别采用更新版RTOG/NRG指南(n=122)或EORTC指南(n=123)。
- 主要终点为治疗相关毒性,PFS和OS为次要终点。
主要发现
- 两组低级别或高级别毒性均无差异,两组均未出现5级毒性,RTOG/NRG组与EORTC组神经毒性无显著差异。
- RTOG/NRG组与EORTC组中位PFS分别为11.0个月(95%CI 7.1-14.9个月)与10.0个月(95%CI 3.8-16.2个月),P=.73。
- RTOG/NRG组与EORTC组中位OS分别为19.5个月(95%CI 14.2-24.8个月)与18.5个月(95%CI 12.8-24.2个月),P=.80。
- 在IDH野生型胶质母细胞瘤患者中,RTOG/NRG组与EORTC组中位PFS分别为8.0个月(95%CI 6.8-9.2个月)与8.0个月(95%CI 7.0-9.0个月),P=.38。
- 在IDH野生型胶质母细胞瘤患者中,RTOG/NRG组与EORTC组中位OS分别为12.0个月(95%CI 7.2-16.8个月)与11.0个月(95%CI 9.7-12.3个月),P=.10。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our study aimed to evaluate the safety and efficacy of radiation therapy (RT) in the treatment of grade 3-4 glioma by comparing the updated Radiation Therapy Oncology Group (RTOG)/National Research Group (NRG) with European Organization for Research and Treatment of Cancer (EORTC) guidelines for target volume delineation. METHODS AND MATERIALS: A total of 245 patients with newly diagnosed World Health Organization grade 3-4 glioma were enrolled and randomly assigned (1:1 ratio) to undergo postoperative RT with concurrent and maintenance temozolomide. The radiation target volume delineation was determined by using either the updated RTOG/NRG (n = 122) or EORTC guidelines (n = 123). The primary endpoint was the toxicity associated with treatment. Progression-free survival (PFS) and overall survival (OS) were considered secondary endpoints. RESULTS: No differences in low- or high-grade toxicities between the 2 groups, and neither group exhibited grade 5 toxicities. No significant differences in neurologic toxicities were observed between the RTOG/NRG and EORTC groups. The median PFS in the RTOG/NRG group and the EORTC group was 11.0 months (95% confidence interval [CI], 7.1-14.9 months) and 10.0 months (95% CI, 3.8-16.2 months), respectively (P = .73). The median OS in the RTOG/NRG group and the EORTC group was 19.5 months (95% CI, 14.2-24.8 months) and 18.5 months (95% CI, 12.8-24.2 months), respectively (P = .80). In patients with isocitrate dehydrogenase wild-type glioblastoma, there were no significant differences between the RTOG/NRG group and the EORTC group in median PFS (8.0 months [95% CI, 6.8-9.2 months] vs. 8.0 months [95% CI, 7.0-9.0 months], P = .38) and median OS (12.0 months [95% CI, 7.2-16.8 months] vs. 11.0 months [95% CI, 9.7-12.3 months], P = .10). CONCLUSIONS: Compared with EORTC principles, postoperative RT according to RTOG/NRG principles did not increase treatment-related toxicities and was equally effective for patients with grade 3-4 glioma, including the subgroup of patients with isocitrate dehydrogenase wild-type glioblastoma.
引用
- Qiu Y, Li Y, Jiang C, et al. Toxicity and Efficacy of Different Target Volume Delineations of Radiation Therapy Based on the Updated Radiation Therapy Oncology Group/National Research Group and European Organization for Research and Treatment of Cancer Guidelines in Patients With Grade 3-4 Glioma: A Randomized Controlled Clinical Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 39615657. doi:10.1016/j.ijrobp.2024.11.094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。